In the management of status epilepticus, which combination is recommended?

Prepare for the Chronic Illness Test. Study with interactive questions and detailed explanations. Be confident in your knowledge!

Multiple Choice

In the management of status epilepticus, which combination is recommended?

Explanation:
In status epilepticus the goal is rapid, reliable control of ongoing seizures. The fastest way to achieve that is with an IV benzodiazepine, which quickly terminates seizures. If seizures persist after this initial step, the next move is to give a loading dose of a second-line anti-seizure medication to maintain suppression and prevent recurrence; fosphenytoin is commonly used for this purpose because it can be given IV, reaches effective levels quickly, and is easier on the veins than phenytoin. So the recommended approach is an IV benzodiazepine to stop the current seizure, followed by a loading dose of fosphenytoin to sustain control. Oral diazepam would be too slow and unreliable in ongoing convulsions, subcutaneous insulin has no role in seizure management, and intramuscular epinephrine is not an antiseizure treatment and is inappropriate for this scenario.

In status epilepticus the goal is rapid, reliable control of ongoing seizures. The fastest way to achieve that is with an IV benzodiazepine, which quickly terminates seizures. If seizures persist after this initial step, the next move is to give a loading dose of a second-line anti-seizure medication to maintain suppression and prevent recurrence; fosphenytoin is commonly used for this purpose because it can be given IV, reaches effective levels quickly, and is easier on the veins than phenytoin. So the recommended approach is an IV benzodiazepine to stop the current seizure, followed by a loading dose of fosphenytoin to sustain control. Oral diazepam would be too slow and unreliable in ongoing convulsions, subcutaneous insulin has no role in seizure management, and intramuscular epinephrine is not an antiseizure treatment and is inappropriate for this scenario.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy